Xilio Development Inc (XLO NASDAQ) stock market data APIs
$0.7465
-0.02(-2.7%)
as of September 15, 2025
Try our APIs with
free plan!
Xilio Development Inc Financial Data Overview
Price chart is built with
Anychart
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Prev. Close
0.7465
Open
0.7292
High
0.7626
Low
0.7292
52 wk Range
0.615-1.7
Market Cap
38 176 K
Shares Outstanding
51 828 K
Revenue
15 001 K
EPS
-0.16
Beta
-0.109
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Xilio Development Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Xilio Development Inc data using free add-ons & libraries
Get Xilio Development Inc Fundamental Data
Xilio Development Inc Fundamental data includes:
- Net Revenue: 15 001 K
- EBITDA: -55 015 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Xilio Development Inc News
New
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
Xilio Therapeutics, Inc. Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated ca...
Xilio Development earnings missed by $0.06, revenue topped estimates
Investing.com - Xilio Development (NASDAQ: XLO) reported second quarter EPS of $-0.160, $0.06 worse than the analyst estimate of $-0.100. Revenue for the quarter came in at $8.21M versus the consens...
Xilio Therapeutics GAAP EPS of -$0.16 misses by $0.06
* Xilio Therapeutics press release [https://seekingalpha.com/pr/20200828-xilio-therapeutics-announces-pipeline-and-business-updates-and-second-quarter-2025-financial] (NASDAQ:XLO [https://seekingalp...
Snap downgraded, Leidos upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
